SHELTON, Conn., Dec. 5, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and...
Hence then, the article about intensity therapeutics granted 180 day extension to regain compliance with nasdaq s minimum bid price requirement was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement )
Also on site :
- Cuban official accuses US of ‘piracy’ against sanctioned Caribbean island
- Numbrix 9 - January 25
- Week in Pictures: From Minneapolis turmoil to Israeli attacks on Gaza